No headlines found.
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Globe Newswire (Fri, 7-Aug 8:00 AM ET)
Globe Newswire (Tue, 23-Jun 8:05 AM ET)
Globe Newswire (Tue, 9-Jun 8:05 AM ET)
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.
Alps Group - Ordinary Share trades on the NASDAQ stock market under the symbol ALPS.
As of August 21, 2026, ALPS stock price was flat at $0.27 with 5,725 million shares trading.
ALPS has a beta of 2.60, meaning it tends to be more sensitive to market movements. ALPS has a correlation of 0.04 to the broad based SPY ETF.
ALPS has a market cap of $44.93 million. This is considered a Sub-Micro Cap stock.
ALPS support price is $.25 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALPS shares will trade within this expected range on the day.